[普萘洛尔治疗增殖期血管瘤血清血管内皮生长因子及基质金属蛋白酶-9的变化]
[The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
作者信息
Zhao Zhong-Fang, Lü Ren-Rong, Huo Ran, Fu Hong-Bing, Xu Guang-Qi
机构信息
Department of Plastic and Burn Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
出版信息
Zhonghua Zheng Xing Wai Ke Za Zhi. 2011 Sep;27(5):359-61.
OBJECTIVE
To study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment.
METHODS
The serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment. The relationship between the serum VEGF, MMP-9 and the prognosis was analyzed.
RESULTS
The serum VEGF (295.4 +/- 158.1) pg/ml was high before treatment, then decreased after 4 weeks and 8 weeks of treatment (255.7 +/- 130.4) pg/ml, (224.2 +/- 120.6) pg/ml. The serum VEGF was significantly lower after 8 weeks of treatment (P < 0.05). The serum MMP-9 was also decreased after treatment, showing a positive relationship with VEGF.
CONCLUSIONS
Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.
目的
研究普萘洛尔治疗前后增殖期血管瘤血清血管内皮生长因子、基质金属蛋白酶-9的水平。
方法
采用酶联免疫吸附测定法检测普萘洛尔治疗前、治疗4周及8周后血清VEGF、MMP-9水平，并分析血清VEGF、MMP-9与预后的关系。
结果
治疗前血清VEGF水平较高，为(295.4±158.1) pg/ml，治疗4周及8周后降低，分别为(255.7±130.4) pg/ml、(224.2±120.6) pg/ml。治疗8周后血清VEGF显著降低(P<0.05)。治疗后血清MMP-9也降低，与VEGF呈正相关。
结论
普萘洛尔可通过降低血清VEGF和MMP-9治疗增殖期血管瘤。
Zotero 插件